Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.09.14	Regeneron: Bayer's Japan Unit Submits Application For EYLEA Injection In Japan (RTTNews)
31.08.14	Sanofi, Regeneron Report Positive Results From Four Pivotal Alirocumab Trials (RTTNews)
25.08.14	Regeneron, Sanofi To Present Results From Four Phase 3 Alirocumab Trials At ESC (RTTNews)
05.08.14	Regeneron Pharma Q2 Profit Increases - Quick Facts (RTTNews)
30.07.14	Sanofi And Regeneron: 9 Phase 3 ODYSSEY Trials Of Alirocumab Met Primary Goal (RTTNews)
30.07.14	ADMP Awaits Decision, REGN Can Catch Your Eye, SQNM Does A Deal, ZLTQ Goes Cool (RTTNews)
18.07.14	Regeneron Reports Results From Phase3 Trial Of EYLEA Injection For DME Treatment (RTTNews)
10.07.14	The Rise And Rise Of Regeneron... (RTTNews)
09.07.14	Regeneron, Sanofi Announce Positive Results From Ph 2b Study Of Dupilumab (RTTNews)
12.06.14	Sanofi, Regeneron Announce Detailed Data From Positive Sarilumab Phase 3 Trial (RTTNews)
08.05.14	Regeneron Q1 GAAP Profit Down - Quick Facts (RTTNews)
05.05.14	Regeneron, Avalanche To Develop Novel Gene Therapy Products In Ophthalmology (RTTNews)
01.04.14	Sanofi, Regeneron Report Positive Results On Alirocumab Phase 2 Japanese Study (RTTNews)
03.03.14	Bayer Submits VEGF Trap-Eye To Treat Diabetic Macular Edema In Japan (RTTNews)
25.02.14	BIOL Has Reason To Smile, CBMG Walks The Talk, CLSN Warms Up, REGN Catches Eyes (RTTNews)
24.02.14	Regeneron Says FDA Accepts For Review SBLA For EYLEA - Quick Facts (RTTNews)
11.02.14	Regeneron Pharma Reports Q4 Net Income Of 0.86 Per Share - Quick Facts (RTTNews)
10.02.14	Regeneron, Bayer Announce Results From Phase 3 VISTA Trial Of EYLEA (RTTNews)
14.01.14	Regeneron, Bayer To Co-develop Eylea Combination Therapy (RTTNews)
19.12.13	Sanofi, Regeneron To Collaborate With ACC For PCSK9 Inhibitor Clinical Program (RTTNews)
19.12.13	ALIM, PSDV Rally After Iluvien News, GILD Lays Out Plan, REGN Gets FDA Date (RTTNews)
18.12.13	Regeneron: FDA Accepts SBLA For EYLEA - Quick Facts (RTTNews)
22.11.13	Regeneron Says EYLEA Got Approval In Japan - Quick Facts (RTTNews)
22.11.13	Sanofi, Regeneron Report Positive Data With Sarilumab In Phase 3 Arthritis Trial (RTTNews)
22.11.13	Sanofi, Regeneron Report Positive Results With Sarilumab In First Phase 3 Trial (RTTNews)
07.11.13	Bayer HealthCare Submits MAA In European Union For EYLEA Injection (RTTNews)
05.11.13	Regeneron Pharma Q3 GAAP Profit Drops - Quick Facts (RTTNews)
21.10.13	Critical Alerts For Cisco, Chipotle Mexican Grill, Regeneron, SolarCity, and ARM Holdings Released By InvestorsObserver (PR Newswire)
21.10.13	Regeneron Pharma Reports Positive Topline Results For EYLEA Injection (RTTNews)
21.10.13	Regeneron Reports Positive Phase 3 Data for EYLEA® (aflibercept) Injection in Macular Edema Following Branch Retinal Vein Occlusion (PR Newswire)
16.10.13	Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar (PR Newswire)
16.10.13	Sanofi, Regeneron Say Alirocumab Significantly Reduces Bad Cholesterol (RTTNews)
23.09.13	Conference Calls, New Appointments, Upcoming Presentations, Prospectus Filings and Acquisition Deal Updates - Research Report on Johnson & Johnson, WellPoint, Regeneron, Onyx, and MannKind (PR Newswire)
19.09.13	Critical Alerts For Cisco Systems, Petroleo Brasileiro S.A., General Motors (GM), Regeneron Pharmaceuticals, and Total S.A. Released By InvestorsObserver (PR Newswire)
18.09.13	Pipeline Developments, Product Recalls, Clinical Trial Results, Recognitions, and New Appointments - Research Report on Johnson & Johnson, Amgen, Regeneron, UnitedHealth, and Bristol-Myers (PR Newswire)
17.09.13	Regeneron to Present Phase 3 Data for EYLEA® (aflibercept) Injection in Diabetic Macular Edema at Upcoming Retina Society Meeting (PR Newswire)
14.09.13	Sanofi Likely To Repurchase 9% Stake Of L'Oreal (RTTNews)
10.09.13	Regeneron Names Robert Landry SVP, Finance & CFO - Quick Facts (RTTNews)
03.09.13	Pharmaceuticals Report Revolutionary Findings, Approved Treatments, Investor Conferences - Research Report on Celgene, Amgen, Biogen Idec, Regeneron, and Questcor (PR Newswire)
29.08.13	Regeneron:EC Oks Eylea Injection To Treat Visual Impairment Due To Macular Edema (RTTNews)
27.08.13	Regeneron Announces Upcoming 2013 Investor Conference Presentations (PR Newswire)
21.08.13	Biotech Companies Announce Financial Results and Receive New Patents - Research Report on Regeneron, Medivation, Incyte, Santarus, and ACADIA (PR Newswire)
19.08.13	Critical Alerts For Microsoft, Amarin, Regeneron Pharmaceuticals, Best Buy, and Harley Davidson Released By InvestorsObserver (PR Newswire)
09.08.13	Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS (PR Newswire)
07.08.13	Regeneron Granted Fundamental Patents Covering Mouse Antibody Technology Used in VelocImmune® Mice (PR Newswire)
06.08.13	Regeneron : Eye Drug Meets Primary Endpoint In Diabetic Macular Edema Trials (RTTNews)
06.08.13	Regeneron Reports Second Quarter 2013 Financial and Operating Results (PR Newswire)
26.07.13	Regeneron Says CHMP Recommends For Approval Of Eylea Injection - Quick Facts (RTTNews)
04.08.09	Regeneron Reports Second Quarter 2009 Financial and Operating Results (Businesswire)
30.04.09	Regeneron Reports First Quarter 2009 Financial and Operating Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	52.18	0.58 %	K V
Part Grp Hldg	1’274.00	0.55 %	K V
Holcim	89.22	0.41 %	K V
Swiss Life Hldg	692.60	0.09 %	K V
Alcon	76.32	0.00 %	K V
Givaudan	4’038.00	-0.57 %	K V
Swisscom	502.50	-0.89 %	K V
Swiss Re	130.65	-0.99 %	K V
Sika	223.30	-1.28 %	K V
Nestle	73.98	-1.65 %	K V

mehr

17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone
05.12.24		Börse New York in Rot: NASDAQ 100 zum Ende des Donnerstagshandels schwächer
19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwacher Handel: NASDAQ 100 am Mittag in der Verlustzone